CVS Pharmacy
CVS Pharmacy is the largest U.S. retail pharmacy chain by store count, with approximately 9,000 locations. It is a subsidiary of CVS Health, which also owns CVS Caremark (one of the three largest pharmacy benefit managers) and the health insurer Aetna, forming a vertically integrated healthcare conglomerate.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated. Last assessed 2026-09-26. Score revised 2026-09-26: 64 → 60.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
Melville Corporation renamed itself CVS Corporation in November 1996, making the drugstore chain a standalone company that grew by acquisition: Revco ($2.8 billion, 1997), Arbor Drugs (1998), Eckerd stores (2004) and MinuteClinic (2006). Stores were conventionally staffed and the market still had many rivals. The main warning sign was a Medicaid billing scheme, begun in 2000, that switched patients to costlier ranitidine capsules and came to light only in 2008.
The Caremark merger in March 2007 joined the largest drugstore chain with a major PBM, putting reimbursement rules for rival pharmacies and dispensing at CVS stores under one roof. CVS paid $36.7 million in 2008 over the ranitidine scheme, began a decade of premature insulin-pen refills in 2010, and approved a $6 billion buyback in 2012. The period closed on a pro-health move: the February 2014 decision to stop selling tobacco.
CVS became CVS Health in September 2014 as tobacco left its shelves, then raised its dividend 27% alongside a $10 billion buyback and in 2015 bought Omnicare ($10.6 billion) and Target's 1,660 pharmacies. Caremark's performance-network clawbacks and 2017 reimbursement cuts squeezed rival pharmacies, and a 2017 lawsuit alleged insured customers paid more than cash prices. Ohio's 2018 Medicaid audit exposed PBM spread pricing, and Congress banned pharmacy gag clauses that October.
The $69 billion Aetna acquisition closed in November 2018, making CVS the only U.S. company combining a national pharmacy chain, a top PBM and a major insurer. CarePass went nationwide in 2019 and the CVS Media Exchange began selling ExtraCare-based ad targeting in 2020, while Kentucky's 2019 Medicaid report and a 2019 AIDS Healthcare Foundation suit over clawbacks spotlighted the PBM side. Pandemic workloads exposed thin staffing: Oklahoma fined four understaffed stores in 2020, a Virginia inspector found a 37% error rate in 2021, and the government joined suits over unauthorized auto-refills.
In November 2021 CVS announced about 900 store closures over three years, weeks before authorizing a $10 billion buyback; that month a federal jury found it helped create the opioid crisis in two Ohio counties, and in 2022 it agreed to a $5 billion opioid settlement. Understaffing peaked: Ohio found patient harm and missing controlled drugs, pharmacy workers walked out in the 2023 Pharmageddon protests, and Ohio imposed record penalties in 2024. CVS bought back $5 billion of stock in 2023-2024 while cutting 5,000 jobs and spending about $18.6 billion on Oak Street Health and Signify Health, and Minnesota fined Caremark for forcing patients to CVS pharmacies.
The board replaced CEO Karen Lynch with Caremark chief David Joyner in October 2024 under activist pressure; buybacks stopped, closures wound down, and 2026 brought the first planned net store growth in years. The legal reckoning continued: a DOJ opioid dispensing suit, Louisiana's text-message lawsuits (settled for $45 million), a $440 million deal on the Omnicare fraud judgment, insulin-pen settlements and a July 2026 FTC consent order on Caremark's rebate and hub conduct. CVS still fights structural reform, suing Arkansas and Tennessee over PBM-ownership bans, and pharmacists voted to authorize a strike in August 2026 after the NLRB found CVS unlawfully refused to bargain.
Alternatives
Mark Cuban's transparent drug pricing platform sells generics at its cost plus a 15% markup, a $5 pharmacy fee and shipping, often far below a chain's cash price. Mostly mail order, which suits maintenance medications, though its Team Cuban Card also works at thousands of affiliated local pharmacies. The catch: savings are concentrated in generics, and cash purchases may not count toward your insurance deductible. Requires a prescription from your doctor.
Costco's pharmacy is known for low cash prices on generic and brand-name drugs. You don't need a Costco membership ($65/year) to fill prescriptions there, though members get extra discounts through the free Costco Member Prescription Program. Easy switch: transfer your prescriptions. The catch: pharmacies sit inside warehouse stores, so there are far fewer locations than CVS.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (71 events)
Melville Corporation Becomes CVS Corporation
Melville Corporation, which had owned CVS since acquiring it in 1969, changed its name to CVS Corporation and moved headquarters to Woonsocket, Rhode Island. The restructuring shed non-pharmacy retail assets and prepared CVS for its consolidation strategy, beginning with the Revco acquisition announcement just months later. The transition from conglomerate subsidiary to independent pharmacy chain enabled CVS's aggressive acquisition-driven growth model.
CVS Acquires Revco for $2.8 Billion
CVS completed its $2.8 billion acquisition of Revco D.S., adding roughly 2,500 stores and giving CVS the largest store count of any U.S. drugstore chain. To settle FTC antitrust charges CVS agreed to divest 120 Revco drugstores or pharmacy counters, 114 stores in Virginia and six pharmacy counters in the Binghamton, New York area, establishing a pattern of consolidation-through-acquisition.
CVS Acquires Arbor Drugs for $1.48 Billion
CVS announced it would acquire Arbor Drugs, a Troy, Michigan chain of 207 stores concentrated in southeastern Michigan, for $1.48 billion, creating the largest chain drug retailer; the deal closed about two months later. Around the same time CVS was closing older strip-mall locations in favor of freestanding sites, accelerating the shift toward large corporate chain retail.
CVS Begins Switching Patients to Costlier Ranitidine Capsules
CVS began systematically switching patients from cheaper ranitidine (Zantac) tablets to more expensive capsule formulations to increase Medicaid reimbursement, a practice that continued through 2006. In Illinois, CVS charged Medicaid $79.80 for 60 capsules versus $17.10 for equivalent tablets. The scheme was eventually exposed by a whistleblower and led to a $36.7 million settlement in 2008 with the U.S. government, 23 states, and the District of Columbia.
CVS Acquires 1,268 Eckerd Stores and PBM Business
CVS purchased 1,268 Eckerd drug stores and Eckerd Health Services, Eckerd's pharmacy benefit management and mail-order pharmacy business, from JCPenney. The deal expanded CVS into Texas, Florida, and other southern states while simultaneously adding PBM capabilities through Eckerd's mail-order operations. The acquisition was part of a growth-through-consolidation strategy driven by shareholder expectations for revenue expansion, establishing the model for CVS's later vertical integration.
CVS Acquires MinuteClinic Walk-In Clinics
CVS acquired MinuteClinic, the nation's leading retail health clinic provider, along with approximately 700 Sav-On and Osco drugstores from Albertsons. The MinuteClinic acquisition expanded CVS's healthcare footprint beyond dispensing into primary care services, creating additional patient touchpoints and cross-selling opportunities.
CVS-Caremark Merger Creates PBM-Pharmacy Giant
CVS Corporation completed its merger with pharmacy benefit manager Caremark Rx on March 22, 2007, creating CVS/Caremark. Valued at about $21 billion when announced in November 2006, the deal was worth roughly $24-26.5 billion at closing after a bidding contest with Express Scripts. At announcement the companies said the combined business was expected to fill or manage over one billion prescriptions a year. Combining the largest drugstore chain with a major PBM created structural conflicts of interest between managing drug benefits and dispensing prescriptions that persist to this day.
CVS Pays $36.7 Million for Medicaid Ranitidine Fraud
CVS Caremark agreed to pay $36.7 million to the U.S. government, 23 states, and the District of Columbia to settle allegations that between 2000 and 2006, the company improperly switched patients from cheaper ranitidine tablets to more expensive capsule versions to increase Medicaid reimbursement. In one example, CVS charged Illinois Medicaid $79.80 for 60 capsules instead of $17.10 for equivalent tablets.
CVS Begins Decade of Premature Insulin Pen Refills
From 2010 through 2020, CVS dispensed more insulin pens than prescriptions called for to patients in Medicare, Medicaid, TRICARE and FEHB, refilled prescriptions before they were needed, and under-reported days-of-supply, which often kept pharmacy benefit managers from detecting the premature refills. CVS's auto-refill program sent customers pickup prompts on refill dates calculated from the understated days-of-supply, and PBM audits repeatedly found the violations and issued chargebacks, yet CVS management failed to fix the long-standing problem. In December 2025 CVS agreed to pay $37.76 million to settle the resulting False Claims Act case, in which the government joined five whistleblower suits, and admitted certain of the alleged conduct.
CVS Caremark Board Approves $6 Billion Share Buyback Program
CVS Caremark's board of directors approved a $6 billion share repurchase program, continuing a pattern of returning capital to shareholders through buybacks. The company repurchased $1.2 billion in shares in Q2 2012 alone. The buyback prioritized shareholder returns while the company simultaneously expanded through acquisitions funded partly by debt, establishing the financial engineering model that would characterize CVS's approach to balancing shareholder returns with massive healthcare acquisitions.
CVS Announces End of Tobacco Sales Across All Stores
CVS Caremark announced it would stop selling all tobacco products at its more than 7,600 locations, becoming the first major U.S. retail pharmacy chain to do so. The decision cost the company approximately $2 billion in annual revenue but was positioned as aligning the business with its emerging healthcare mission. Sales ended September 3, 2014, a month ahead of the original October deadline.
CVS Health Hikes Dividend 27%, Sets $10 Billion Buyback
CVS Health's board approved a 27% increase in the quarterly dividend to $0.35 per share and a new $10 billion share repurchase authorization to be completed over several years. The capital return came as the company pursued debt-funded acquisitions and set the pattern of large buybacks alongside its healthcare expansion.
CVS Acquires Omnicare for $10.6 Billion
CVS Health agreed to acquire Omnicare, the largest long-term care pharmacy provider in the United States, for $10.6 billion plus $2.3 billion in assumed debt. The acquisition extended CVS's reach into nursing homes and assisted living facilities, adding captive patient populations with high prescription volumes and limited ability to choose alternative pharmacies.
CVS Buys All 1,660 Target Pharmacies
CVS Health agreed to acquire Target Corporation's pharmacy and clinic businesses, including more than 1,660 pharmacies in 47 states. The deal expanded CVS into new markets including Seattle, Denver, Portland, and Salt Lake City, further consolidating the retail pharmacy landscape.
CVS Pays $450,000 to Settle Rhode Island Drug Diversion Claims
CVS Health agreed to pay $450,000 to resolve U.S. allegations that several of its Rhode Island stores violated the Controlled Substances Act by filling forged prescriptions with invalid DEA numbers, filling hydrocodone prescriptions written by psychiatric nurse practitioners who were not permitted to prescribe it, and keeping deficient records. CVS denied wrongdoing.
Lawsuit Reveals CVS Charges More With Insurance Than Cash
A class-action lawsuit filed in federal court alleged that CVS charged customers more for generic drugs when they used insurance than if they had paid cash. The named plaintiff paid $165.68 for a prescription that would have cost $92 without insurance, and the suit alleged CVS stayed silent about the cheaper cash price. CVS called the allegations baseless.
CVS Caremark Slashes Pharmacy Reimbursements Ahead of Aetna Deal
In late 2017 and early 2018, within months of announcing its Aetna acquisition, CVS Caremark sharply cut reimbursements to community pharmacies in Ohio, Arkansas, Iowa, New Jersey, New York and possibly other states. The Ohio Department of Insurance received 40 complaints about CVS Caremark in 2017, 35 of them in the fourth quarter. One Cincinnati pharmacy said Caremark paid 54 cents per pill for generic Antivert when the cheapest wholesale price she could find was 95 cents, while CVS was also sending letters offering to buy out struggling pharmacies.
Ohio Audit Reveals $225 Million in PBM Spread Pricing
Ohio auditors found nearly $225 million in spread pricing by PBMs managing the state's Medicaid program, where PBMs charged payers significantly more than they reimbursed pharmacies and pocketed the difference. CVS Caremark was one of the PBMs involved. The audit led to Ohio banning spread pricing in its Medicaid managed care contracts.
Federal Gag Clause Ban Signed Into Law
President Trump signed the Know the Lowest Price Act and the Patients' Right to Know Drug Prices Act, banning PBM gag clauses that prevented pharmacists from telling patients when a drug's cash price was lower than their insurance copay. Prior to the ban, a 2016 survey found 39% of pharmacists reported gag clauses prevented them from informing patients about lower prices 10-50 times per month.
CVS Completes $69 Billion Aetna Acquisition
CVS Health completed its $69 billion acquisition of Aetna ($78 billion including assumed debt), combining the largest retail pharmacy chain and the CVS Caremark PBM with a health insurer that had about 22 million health plan members and served nearly 45 million people overall. The DOJ required Aetna to divest its standalone Medicare Part D business to WellCare to approve the deal, but the fundamental vertical integration was preserved.
Kentucky Report Finds PBMs Kept $123.5 Million Medicaid Spread
A Kentucky Cabinet for Health and Family Services report found the state's two Medicaid PBMs took in $123.5 million in 2018 by paying pharmacies less than they charged Medicaid for the same prescriptions. CVS Caremark was the largest PBM in Kentucky Medicaid, and pharmacists said PBM pricing information was hard to obtain.
CVS Expands CarePass Paid Membership Nationwide
After pilots in Boston, Philadelphia and Tampa, CVS expanded CarePass nationwide: a $5/month or $48/year paid membership offering free delivery of prescriptions and drugstore items, discounts on CVS-brand products, a monthly $10 coupon and a pharmacist hotline. The program layers subscription revenue on top of the pharmacy relationship and gives members benefits they would lose by transferring prescriptions.
AIDS Healthcare Foundation Sues Caremark Over Pharmacy Clawbacks
AIDS Healthcare Foundation sued CVS Caremark over performance-network fees clawed back from its pharmacies' Part D reimbursements, a program Caremark imposed on network pharmacies starting in 2016. An arbitrator ruled for AHF in November 2021 and ordered Caremark to pay $23 million, and a federal court upheld the award in 2022.
Government Intervenes in Whistleblower Suits Over CVS and Omnicare Auto-Refills
The federal government, 29 states and the District of Columbia intervened in whistleblower suits alleging that CVS subsidiary Omnicare and CVS dispensed drugs without valid prescriptions, relying on computer systems that auto-populated refills (as many as 99 for Medicare Part D patients) without a physician's renewed authorization. Separately, Omnicare paid $15.3 million in May 2020 to settle allegations that it dispensed controlled substances without valid prescriptions.
Oklahoma Fines CVS $125,000 Over Misfills at Understaffed Stores
The Oklahoma pharmacy board fined CVS $125,000 over prescription errors and inadequate staffing at four stores, finding a 21% misfill rate in Bartlesville, a backlog of unfilled prescriptions at an understaffed Choctaw store, and harm to a child in Owasso, which was placed on probation.
CVS Launches Retail Media Network Built on ExtraCare Data
CVS Pharmacy launched the CVS Media Exchange ad network in August 2020, selling brands targeting built on decades of ExtraCare loyalty data across CVS's digital channels. By 2025 the network was expanding off-site to programmatic and connected-TV ads through a self-serve partnership with The Trade Desk.
Aetna Launches Plan Steering Members to CVS Locations
CVS-owned Aetna rolled out Aetna Connected, an employer plan for the Kansas City market starting in 2021 that gives members no-copay visits at CVS MinuteClinics and HealthHUBs, free CVS prescription delivery and CVS store discounts, steering them toward its parent's locations. Former FTC policy director David Balto said the design would likely mean less choice and higher costs, and CVS said it expected some added front-store revenue from the plan.
CEO Larry Merlo Realizes Over $223 Million in Compensation Since 2011
Analysis by Equilar revealed that CVS Health CEO Larry Merlo had realized over $223 million in total compensation between 2011 and 2019. Fortune Magazine identified Merlo as having the highest CEO-to-average-employee pay ratio of any American company. The disparity between executive compensation and frontline pharmacy worker wages became increasingly conspicuous as the company pursued cost-cutting in its retail operations.
Karen Lynch Succeeds Larry Merlo as CVS Health CEO
Aetna president Karen Lynch became CVS Health's president and CEO on February 1, 2021, succeeding Larry Merlo, who had led the company since 2011. The board framed the change as the next phase of the company's transformation after the Aetna integration.
Virginia Inspector Finds 37% Error Rate at Understaffed CVS Pharmacy
Virginia Mercury reported on an understaffed CVS pharmacy in Virginia Beach where a state inspector reviewed 200 prescriptions and found 74 mistakes, an error rate of roughly 37%. Former employees described pharmacists at high-volume stores filling 500 to 1,000 prescriptions a day while also running drive-throughs, giving vaccines, and counseling patients, and said understaffing had worsened for years.
CVS Announces 900 Store Closures Over Three Years
CVS Health announced plans to close about 900 stores over three years starting in spring 2022, roughly 300 a year and about 9% of its nearly 10,000 U.S. stores. The company cited shoppers buying more online and changes in population, customer habits and health needs. The closures later contributed to growing pharmacy deserts.
Federal Jury Finds CVS Helped Fuel Opioid Crisis in Ohio Counties
In the first completed trial of pharmacy chains over opioids, a federal jury found that CVS, Walgreens and Walmart helped create a public nuisance by recklessly dispensing massive quantities of painkillers in Lake and Trumbull counties, Ohio. The chains said they would appeal.
CVS Authorizes $10 Billion Buyback and 10% Dividend Increase
Three weeks after announcing 900 store closures, CVS Health announced plans to buy back $10 billion of shares and raise its annual dividend by 10%, alongside a forecast of at least $290 billion in revenue for 2021.
FTC Opens 6(b) Inquiry Into PBMs Including CVS Caremark
The FTC launched an inquiry into pharmacy benefit managers, sending compulsory orders to the six largest PBMs including CVS Caremark. The inquiry focused on the impact of vertically integrated PBMs on drug affordability and access, including rebates, fees, and steering of patients to PBM-affiliated pharmacies.
CVS Agrees to $5 Billion Opioid Settlement
CVS Health agreed to pay approximately $5 billion over 10 years to settle thousands of lawsuits by state, local, and Native American tribal governments over its role in the opioid crisis. The settlement resolved allegations that CVS pharmacies recklessly dispensed opioid prescriptions without adequate safeguards. CVS did not admit wrongdoing. The settlement was the first by a major pharmacy chain.
CVS Acquires Oak Street Health and Signify Health for $18.6 Billion
CVS Health completed acquisitions of Signify Health ($8 billion, home healthcare) and Oak Street Health ($10.6 billion, value-based primary care with 169 medical centers). These acquisitions deepened CVS's vertical integration by adding home health assessments and primary care clinics to its pharmacy-PBM-insurer stack, further consolidating patient touchpoints.
Minnesota Fines Caremark for Forcing Patients to CVS Pharmacies
Minnesota's Commerce Department fined Caremark $500,000 for steering members to pharmacies it owns. Under the Maintenance Choice program, about 72,000 Minnesotans had to use a CVS retail or mail-order pharmacy after their first three maintenance fills, and some said they had to drive up to 130 miles. Caremark must open the program to any pharmacy accepting standard terms.
Ohio Finds Patient Harmed, 1,800 Controlled Drug Doses Missing at Understaffed CVS
The Ohio Board of Pharmacy released inspection reports for a CVS pharmacy in Willoughby, Ohio, finding the loss of 1,800 doses of controlled substances and a patient harmed after being given the wrong medication. The reports followed earlier findings of hundreds of problems at eight other understaffed Ohio CVS stores, including weeks-long prescription delays, poor narcotics controls, and expired drugs on shelves.
CVS Health Cuts 5,000 Jobs
CVS Health said it would cut about 5,000 jobs, mostly corporate roles, to reduce costs as it pushed further into health care services after buying Signify Health. The company had about 300,000 U.S. employees.
Kansas City CVS Pharmacists Stage First Walkout Over Unsafe Conditions
CVS pharmacists in the Kansas City area walked off the job in September 2023, forcing at least a dozen stores to close, to protest unsafe working conditions tied to understaffing. They said CVS had cut technician hours even as demand for prescriptions and vaccines grew; CVS's chief pharmacy officer apologized and promised more staff hours and lower vaccination goals. The action marked the beginning of a broader national movement.
Pharmageddon: Pharmacy Workers Stage Three-Day National Walkout
Non-union pharmacists and pharmacy technicians at CVS and Walgreens began a three-day walkout dubbed 'Pharmageddon' to protest working conditions they said made it hard to fill prescriptions safely. UPI reported as many as 4,500 participants on the first day, while organizers gave NBC News an estimate of about 900 people in up to 10 states. Workers demanded more staff, adequate technician hours, and an end to productivity quotas.
CVS Spends $3 Billion on Accelerated Share Buyback
CVS Health paid $3.0 billion on January 4, 2024 for an accelerated share repurchase, after a $2.0 billion buyback in January 2023, while it was closing hundreds of stores. It repurchased no shares in 2025.
Ohio Fines CVS $250,000 for Unsafe Pharmacy Staffing
The Ohio Board of Pharmacy fined a CVS store in Canton $250,000 and placed it on at least three years of probation after investigators found it so understaffed that it was over a month behind on filling prescriptions. The board said it had 22 more cases pending against 20 other Ohio CVS stores.
CVS Settles 27 Ohio Cases for Record $1.5 Million
CVS Health agreed to pay Ohio $1.5 million to settle 27 cases of unsafe pharmacy conditions across 22 stores, the largest fine in Ohio Board of Pharmacy history. Issues found during 2020-2023 inspections included insufficient staffing, dispensing errors, prescription delays, dirty conditions, expired medications, and failure to report controlled substance losses. Eight stores were placed on three-year probation.
FTC Sues CVS Caremark for Artificially Inflating Insulin Prices
The Federal Trade Commission sued CVS Caremark, Express Scripts, and OptumRx for engaging in anticompetitive rebating practices that artificially inflated insulin list prices. The FTC alleged these PBMs created a 'perverse drug rebate system' prioritizing high rebates over low list prices, systematically excluding lower-cost insulins in favor of high-price, high-rebate products while collecting billions in rebates and fees.
CVS Lays Off 2,900 Corporate Employees in Cost-Cutting Drive
CVS Health laid off approximately 2,900 employees as part of a $2 billion cost-saving initiative, following 5,000 job cuts the previous year. The layoffs came alongside a strategic review exploring a potential breakup of the company's retail and insurance divisions. CEO Karen Lynch was replaced by David Joyner on October 18 after the company's stock underperformed significantly.
CVS Attempts to Disqualify FTC Commissioners From PBM Case
CVS Health, UnitedHealth Group, and Cigna demanded that FTC Chair Lina Khan and Commissioners Alvaro Bedoya and Rebecca Kelly Slaughter recuse themselves from the PBM insulin pricing case, arguing their public statements showed 'serious bias' against pharmacy benefit managers.
CVS Replaces CEO Karen Lynch With Caremark Chief David Joyner
CVS Health replaced CEO Karen Lynch with longtime pharmacy benefits executive David Joyner, effective October 17, 2024, after its shares fell nearly 20% that year and activist shareholder Glenview Capital pushed for changes. The board had weighed breaking up the insurance and retail businesses but kept the company intact. Joyner's tenure brought a halt to share buybacks, the end of the store-closure program and a series of settlements of legacy litigation.
7,000+ CVS Workers Ratify Union Contract After California Strikes
Over 7,000 UFCW members working at CVS locations across California ratified a three-year contract on November 8, 2024, after months of negotiations and a three-day unfair labor practice strike in Los Angeles and Orange counties. The contract included raises every year, new longevity rates producing wage increases of close to 20% over three years, elimination of the two-tier wage scale for some classifications, and an increased health care bonus.
DOJ Sues CVS for Knowingly Filling Illegal Opioid Prescriptions
The Department of Justice filed a civil lawsuit accusing CVS of 'unlawfully dispensing massive quantities of opioids' from known pill mills, violating the Controlled Substances Act. The complaint, originating from a whistleblower, described 10 patients who died after filling illegal prescriptions at CVS and alleged the company's production metrics led pharmacists to ignore red flags. CVS continued filling prescriptions for one Alabama doctor even after internal notes warned he was under investigation.
FTC Sues CVS to Enforce PBM Investigative Compliance
FTC staff filed petitions in federal court to enforce civil investigative demands issued more than a year earlier to CVS Health and Cigna in an investigation of the pharmacy-related practices of the companies that own the three dominant PBMs. Chair Lina Khan said CVS had produced only a fraction of the required documents and had refused to provide testimony on its compliance efforts despite a Commission order.
Four States Sue CVS for Overcharging Medicaid Programs
Attorneys general from Massachusetts, Connecticut, Oklahoma, and Indiana sued CVS alleging it submitted false and fraudulent claims to state Medicaid programs by failing to bill them the lower prices it offered cash-paying customers through discount card programs run with ScriptSave. The states alleged CVS had not submitted its usual and customary prices to Medicaid since 2016.
CVS Uses Patient Data to Lobby Against Louisiana PBM Reform
CVS sent mass text messages to thousands of pharmacy customers in Louisiana using patient prescription data to lobby against House Bill 358, which would prohibit companies from owning both a PBM and a pharmacy. The texts warned that if the bill passed, their CVS pharmacy could close and medication costs could rise. Louisiana Attorney General Liz Murrill launched a HIPAA investigation, and the U.S. House Oversight Committee opened a parallel probe.
CVS Caremark Ordered to Pay $95 Million in Medicare Fraud Case
A federal judge in Philadelphia ordered CVS Caremark to pay $95 million in a False Claims Act case brought by former Aetna actuary Sarah Behnke in 2014, alleging Caremark misrepresented drug costs so that Medicare Part D was overbilled. In August 2025 the judge trebled the damages and added penalties for a total of about $290 million.
Court Blocks Arkansas Ban on PBM-Owned Pharmacies After CVS Suit
A federal judge preliminarily enjoined Arkansas' Act 624, which would have barred PBMs from owning pharmacies in the state from 2026, after CVS Caremark, Express Scripts, Optum Rx and the PBM trade group sued. The judge found the law likely violates the Commerce Clause and conflicts with TRICARE. CVS had said the law would force it to close its Arkansas pharmacies.
CVS Settles MassHealth Overcharging for $12.25 Million
Massachusetts Attorney General Andrea Joy Campbell announced a $12.25 million settlement with CVS for charging MassHealth higher prices than it offered cash-paying customers through its ScriptSave discount program. CVS was required to implement annual reconciliation of its Medicaid pricing going forward.
CVS Completes Rite Aid Asset Purchases, Absorbing 9 Million Patients
CVS Pharmacy completed its purchase of Rite Aid assets after Rite Aid's liquidation: it took over 63 former Rite Aid and Bartell Drugs stores in Idaho, Oregon and Washington and bought the prescription files of 626 more pharmacies in 15 states. CVS said it now serves more than nine million former Rite Aid and Bartell patients, further consolidating retail pharmacy.
CVS Pays $18.2 Million Over False Medi-Cal Claims
California and the U.S. Department of Justice settled allegations that from 2010 to 2021 CVS submitted Medi-Cal pharmacy claims with false electronic certifications that patients had qualifying medical conditions, without verifying or documenting them. CVS agreed to pay about $18.2 million.
CVS Pays $37.76 Million and Admits Insulin Pen Over-Dispensing
CVS agreed to pay $37.76 million to resolve False Claims Act allegations that from 2010 through 2020 it billed Medicare, Medicaid, TRICARE and the federal employee health program for premature insulin-pen refills, dispensed more insulin than prescriptions called for and under-reported days of supply. As part of the settlement CVS admitted that its pharmacies dispensed more insulin to beneficiaries than they needed.
House Judiciary Finds CVS May Have Violated Antitrust Laws
The House Judiciary Committee's Antitrust Subcommittee released an interim report titled 'When CVS Writes the Rules' concluding that CVS Health may have violated federal antitrust laws. The report documented how CVS monitored independent pharmacies for hub partnerships, revised its provider manual to prohibit hub relationships, and deployed audits and cease-and-desist letters against pharmacies working with competitors like Blink and Phil. The committee found CVS reversed course only after the investigation began.
CVS Pays $45 Million to Settle Louisiana Text-Message Lawsuits
Louisiana settled its three lawsuits against CVS Health and its PBM for $45 million. The state had accused CVS of unfair, deceptive and unlawful practices, including using customer information for a June 2025 text-message campaign against a PBM reform bill.
CVS Floods Tennessee With Ads and Texts Against PBM Ownership Bill
CVS spent $1.3 million on TV ads in all six Tennessee markets and sent text alerts urging people to contact lawmakers against a bill barring PBM owners from owning pharmacies, warning it would close all 134 of its Tennessee pharmacies and eliminate 2,000 jobs. The bill followed a Tennessee Department of Commerce and Insurance audit that found CVS reimbursed its own stores up to 16,500% more for certain drugs than unaffiliated pharmacies.
CVS Plans First Net Store Growth in Years, Opens Pharmacy-Only Format
CVS opened its second pharmacy-only store, in Chicago, and said it would open about 20 such small pharmacies and more than 40 traditional and Target-based pharmacies in 2026, while closing only a few dozen locations. The plan follows four years in which CVS closed about 1,100 locations and opened about 200.
Tennessee Bans PBM-Owned Pharmacies; CVS Sues Within Hours
Tennessee's governor signed a law barring PBMs from owning pharmacies, which effectively targets CVS as the only company in the state that owns both. CVS sued in federal court hours later, arguing the law is unconstitutional; it said it would otherwise have to close 136 retail and specialty pharmacies and halt mail-order service in the state.
CVS Pays $36.5 Million to States Over Insulin Medicaid Overbilling
A bipartisan coalition of 37 state attorneys general and the Justice Department secured $36.5 million from CVS Pharmacy over allegations that from 2010 to 2020 it dispensed more insulin to Medicaid recipients than prescribed and refilled insulin pens early while under-reporting days of supply.
Florida Attorney General Investigates CVS Self-Preferencing
Florida's attorney general issued a civil investigative demand to CVS Health, owner of Caremark and roughly 800 Florida pharmacies, examining whether it steers patients to its own stores, reimburses them more generously than independents, and uses audits and restrictive contracts against small pharmacies.
CVS and Omnicare Agree to Pay $440 Million on $949 Million Fraud Judgment
CVS Health and its long-term-care pharmacy unit Omnicare agreed to pay the Justice Department $440 million to resolve a $948.8 million judgment. A federal jury had found in April 2025 that Omnicare submitted more than 3.3 million false claims for drugs dispensed without valid prescriptions between 2010 and 2018; Omnicare filed for Chapter 11 in September 2025.
FTC Settles Insulin Case With Caremark, Bars Hub Interference
The FTC settled its 2024 insulin case against CVS's Caremark. The consent order delinks PBM fees from drug list prices, requires insulin out-of-pocket caps, lets community pharmacies shift to cost-plus reimbursement, and bars Caremark from interfering with pharmacies' use of hub services, the conduct documented by the House Judiciary Committee, under a monitor. The FTC estimated up to $8.5 billion in consumer savings over ten years.
NLRB Rules CVS Unlawfully Refused to Bargain With Pharmacists' Union
The National Labor Relations Board found that Rhode Island CVS Pharmacy LLC violated federal labor law by refusing to recognize and bargain with The Pharmacy Guild after pharmacists at its Wakefield, Westerly and Middletown stores voted to unionize in 2024, and ordered it to bargain.
Unionized CVS Pharmacists in Three States Authorize Strike
Unionized CVS pharmacy workers in Rhode Island, California and Arizona voted to approve a strike sanction, by margins of 90.3% to 100%, over what they called unsafe staffing and heavy workloads after two years without a first contract. CVS said it has invested in staffing and that union members are under 1% of its roughly 90,000 pharmacy employees.
CVS Settles Criteo Data-Sharing Class Action for $20.5 Million
CVS agreed to a $20.5 million class settlement of claims that it disclosed personal data collected on its website and app to advertising company Criteo. Anyone who used CVS's digital properties before July 27, 2026 qualifies for a $5 or $10 payment; CVS denied violating any law.
Evidence (57 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (8 entries)
Checked 90 items + prose. 35 verified, 40 corrected (18 date-only), 14 re-sourced, 1 removed (unsourced Aetna-steering item). Key fixes: $10B buyback/27% dividend hike misdated to 2025 (was Dec 2014); fake 1996 IPO milestone (Melville rename); Louisiana texts 2025 not 2024; Pharmageddon size, Ohio case counts, Oklahoma error rate, '400-500 per shift' and Caremark deal size/rank corrected; several mismatched URLs re-sourced.
64->60. D1 8->6 (recalibration: closures and understaffing fit 'significant degradation' 6-7, not 'shadow of former self'; 2026 net store growth), D3 6->5 (event: no buybacks since 2025, reinvestment in ~60 new stores; 2023-24 buybacks with layoffs scored in prior era), D9 8->7 (recalibration: walkouts, NLRB refusal-to-bargain ruling, layoffs alongside buybacks fit 6-7; no whistleblower retaliation or buyback-funded layoffs documented). D2, D4-D8, D10 unchanged. Eras: all six re-dated to inflection events (1997-01-01->1996-11-01 Melville becomes CVS Corp, relabeled 'National Chain Rollup'; 2007-03-01->2007-03-22 Caremark; 2015-01-01->2014-09-03 CVS Health rebrand; 2019-01-01->2018-11-28 Aetna close; 2022-01-01->2021-11-18 900-closure plan; 2026-02-15->2024-10-17 Joyner replaces Lynch, relabeled 'Regulatory Confrontation'->'Turnaround Under Scrutiny'). Era scores re-derived from criteria: 16/29/39/47/61/60. Since Sep 2025: Rite Aid asset purchase (9M patients), insulin-pen ($37.76M, $36.5M), Medi-Cal ($18.2M), Louisiana ($45M) and Omnicare ($440M) settlements, Tennessee ad/text campaign then suit against PBM-ownership ban, Florida AG CID, FTC-Caremark consent order, NLRB refusal-to-bargain ruling and strike authorization, Criteo privacy settlement, zero buybacks, ~60 store openings planned for 2026. Description updated (Caremark no longer the largest PBM).
Checked 2 alternatives. Costco: removed unsupported staffing-ratio claim, clarified non-member access. Cost Plus Drugs: removed unsupported '80-90% cheaper', corrected outdated 'mail-order only' (affiliate pharmacy network exists).
Checked 11 removed/trimmed claims: 1 restored, 5 partly restored, 4 confirmed removed, 1 already present. Restored: Revco divestiture split 114 Virginia stores + 6 Binghamton NY counters (FTC 1997-05-30, evidence added). Partly: Caremark merger 'over one billion prescriptions a year' (SEC 8-K 2006-11-01, evidence added); insulin auto-refill prompts and repeated PBM audit findings (DOJ SDNY); Aetna 22 million health plan members (Axios 2018-11-28, evidence added); Aetna steering narrowed to 2020 Aetna Connected Kansas City plan (Healthcare Dive, timeline item added); Pharmageddon context 2022 Kansas Board survey 57% (Kansas Pharmacists Association, evidence added). Confirmed removed: Arbor 'first Michigan footprint' (Crain's says CVS already had a handful of Michigan stores) and 180/200 store figures; NBC '5-10x cash price'; Caremark ~30% share in 2022; Canton fine as part of $1.5M settlement. Already present: FTC second PBM report (evidence).
Triaged 2026-06-29; no rescore warranted (no material change since baseline, or changes sub-threshold).